Music icon Billy Joel faced a personal health battle recently, as he was diagnosed with Normal Pressure Hydrocephalus (NPH) in May 2025. This neurological disorder, characterized by an abnormal buildup of cerebrospinal fluid (CSF) in the brain’s ventricles, led to increased pressure and a range of debilitating symptoms that briefly halted his illustrious career.
Joel reported experiencing poor balance, a disorienting ‘rocking motion’ sensation as if he were constantly on a boat, general unsteadiness, and noticeable memory issues. The diagnosis prompted a difficult decision, as NPH’s primary treatment involves brain surgery to implant a shunt that drains the excess CSF. Despite initial hesitation about undergoing such a procedure, Joel proceeded after research indicated that timely intervention could significantly improve his balance and memory, and recognizing the condition’s potential to worsen if left untreated.
The surgery proved to be a turning point. Following the shunt implantation, Joel reported marked improvements in his memory, better balance, and enhanced overall function. He publicly stated, “I’m not going anywhere, I’m still here,” conveying a powerful message of resilience. By March 2026, his daughter, Alexa Ray, confirmed he was “doing great” and consistently undergoing physical therapy as part of his recovery.
This health challenge necessitated a temporary pause from the stage. All of Joel’s upcoming concert performances scheduled for 2025 and 2026 were canceled. Medical professionals advised him to cease performing during his recovery period, explaining that the concussive physical impact of loud, high-energy rock concerts had contributed to his brain trauma and had worsened his NPH symptoms, affecting his hearing, vision, and balance. Joel expressed regret for disappointing his dedicated fanbase but affirmed his commitment to prioritizing his health, while also conveying hope for future performances.
Fans got a glimpse of his return to form in January 2026, when Joel made his first public performance since his diagnosis, playing two songs with a cover band. This quiet return was a significant step on his path to recovery.
Joel’s public disclosure of his NPH diagnosis is expected to raise much-needed awareness for this frequently misunderstood and under-diagnosed condition. NPH primarily affects individuals aged 60 and older, and its key symptoms – gait disturbances, cognitive impairment, and urinary incontinence – are often misdiagnosed as other age-related neurodegenerative diseases like Alzheimer’s or Parkinson’s. However, NPH is unique among such conditions, earning the moniker ‘treatable dementia’ because, unlike many degenerative diseases, it can be effectively treated and potentially reversed with timely intervention, primarily through the surgical implantation of a ventriculoperitoneal (VP) shunt. While an estimated 700,000 Americans may have NPH, fewer than 20% receive a proper diagnosis, underscoring the critical importance of early detection and treatment for a favorable prognosis.